When the Guardian Loses Its Partner: p53 Surges While KAISO Collapses in Oral Cancer Tissue
Deep in the lining of the mouth, one of biology’s most celebrated molecular alliances appears to be quietly falling apart. In a new study published in the journal BMC Cancer, researchers at Dow University of Health Sciences in Karachi report that two proteins which normally act as partners in defending cells against cancer — the famous tumor suppressor p53 and its transcriptional accomplice KAISO — swing in opposite directions inside oral tumors. Analyzing tissue from fifty patients with oral squamous cell carcinoma, the team found p53 surging to its highest levels in the core of the tumor, while KAISO, the very protein that p53 helps to switch on during the earliest moments of the DNA damage response, fell to its lowest. The subcellular geography of both molecules was scrambled as well, with each losing the nuclear and cytoplasmic balance that marks healthy tissue. To the authors, the message is stark: somewhere along the road to malignancy, one or both of these partner proteins appears to have been functionally altered, defying the established relationship between them.
At the center of the story sits TP53, the gene whose mutations are the most frequent among the genetic aberrations found in human cancers. The gene encodes a 43.65-kilodalton protein that functions as the hub of the cell’s stress-response system. When ultraviolet light, chemical mutagens, oncogene activation, or other insults strike, p53 decides the cell’s fate: it can impose cell-cycle arrest until repairs are completed, trigger apoptosis if the damage is beyond saving, drive senescence, mobilize DNA repair machinery, or shift metabolic activity to help the cell weather the storm. In effect, p53 converts stress signals into decisions that keep damaged cells from multiplying uncontrollably. Because so much of cancer biology flows through this single node, aberrations in TP53 produce irregularities across the entire stress-response network and open the door to cancerous transformation. That is why researchers have spent decades tracking where p53 accumulates, which cellular compartment it occupies, and what its abundance reveals about a tumor’s behavior and a patient’s outlook.
Less famous but increasingly consequential is KAISO, the protein product of the ZBTB33 gene. KAISO belongs to a family of transcriptional regulators built around a protein-interaction domain and a set of zinc fingers that grip specific DNA sequences. Earlier work had established a direct line of command between the two partners: during early DNA damage responses, p53 binds to dedicated TP53-responsive DNA elements, known as p53-responsive elements or p53REs, and activates transcription of KAISO. In other words, when the guardian of the genome sounds the alarm, KAISO is one of the recruits it summons to the scene. Previous studies had also reported that significant expression patterns of KAISO play a role in determining field cancerization in patients with oral cancer, the phenomenon in which broad stretches of mucosa surrounding a tumor carry precancerous molecular change. The working expectation was therefore straightforward: wherever p53 rises, KAISO should follow. The new data overturn that assumption in the most direct way possible.
To capture these patterns, the team, working between 2024 and 2025 with approval from the Institutional Review Board of Dow University of Health Sciences under number IRB-1319/DUHS/Approval/2019, and in accordance with the principles of the 1964 Helsinki Declaration, recruited fifty patients with oral squamous cell carcinoma, all of whom provided written informed consent. From each patient the researchers obtained three kinds of oral mucosa specimens: a sample from the tumor core itself, a sample from the tumor-free peripheral region taken after the tumor had been excised, and a sample from the opposing, non-diseased buccal mucosa on the opposite side of the mouth. Fifty additional volunteers who were undergoing elective wisdom tooth removal contributed normal mucosa samples that served as healthy controls. This three-point sampling strategy was deliberate. Rather than comparing only tumor against normal tissue, the design allowed the investigators to trace how protein expression shifts across a gradient running from visibly malignant tissue, through the surgically critical margin, into mucosa that looks entirely healthy to the naked eye.
The concept anchoring that design is field cancerization, an idea with deep roots in oral oncology. Rather than viewing a mouth tumor as an isolated island of disease, field cancerization treats the visible lesion as the most dramatic expression of a widespread process: broad territories of epithelium, exposed to the same carcinogenic pressures over years, accumulate genetic and epigenetic damage in parallel. A tumor removed by the surgeon may therefore be only the visible summit of a subvisible mountain range. Clinically, the concept helps explain why oral cancers so often return near the site of resection and why second tumors can arise in tissue that appeared normal at the time of the first operation. Mapping the molecular state of the field — the peripheral margin and the opposing mucosa in this study — offers a way to visualize that hidden landscape. If p53 and KAISO behave abnormally even in apparently healthy areas, the field itself may be quietly betraying its molecular history.
Technically, the investigation rested on immunohistochemistry, a technique in which antibodies engineered to recognize a specific protein are applied to thin sections of preserved tissue, binding wherever the target is present, while an enzyme-linked visualization step deposits a colored precipitate that marks the protein’s location and relative abundance under the microscope. The specimens were processed for TP53 and KAISO expression, producing stained slides that the team quantified with Image-J software, an open-source image-analysis platform widely used in laboratory research. Rather than relying on subjective visual scoring, the researchers measured staining intensity across the tissue and calculated optical density, a semi-quantitative optical measure that rises with the amount of chromogen deposited in each cellular compartment. Optical densities were derived separately for nuclear and cytoplasmic staining, which is precisely what allowed the investigators to compare how each protein was distributed inside the cell. The resulting values were then subjected to statistical analysis capable of distinguishing true biological shifts from measurement noise across tumor cores, margins, opposing mucosa, and controls.
The between-region results were unambiguous. TP53 expression was significantly increased in the tumor core compared with the peripheral region, the opposing mucosa, and the controls, with a P-value below 0.0001 — the statistical signature of a difference far too large to be attributed to chance. KAISO moved in the mirror image: its expression was significantly decreased in the tumor core relative to the periphery, the opposing mucosa, and the controls, also at a P-value below 0.0001. In healthy and peritumoral tissue, then, the two proteins maintain a relationship that the tumor core inverts: the stress-response hub floods upward while its transcriptional partner drains away. For a regulatory system in which p53 is supposed to summon KAISO into action, the simultaneous rise of one and fall of the other within the same tissue is exactly the kind of discordance that signals the circuit itself has been damaged rather than merely dialed up or down.
The subcellular analysis sharpened the picture further. In the tumor core, TP53 displayed a significant difference in expression between the nucleus and the cytoplasm, with a P-value of 0.0003, a compartmental shift that was entirely absent in the control specimens. KAISO displayed the inverse behavior: control tissue showed a significant difference between nuclear and cytoplasmic expression, with a P-value below 0.0001, and that distinction was completely lost in the tumor specimens. Localization matters because both of these are nuclear operators by trade. A transcription factor that abandons its disciplined nuclear distribution — or whose nuclear-versus-cytoplasmic contrast disappears altogether — cannot reliably find the DNA sequences it is meant to regulate. The loss of KAISO’s nuclear-cytoplasmic contrast in tumors, paired with p53’s newly compartmentalized pattern, suggests that the trafficking and balance of both proteins are disturbed in malignancy. The authors conclude that the two proteins show opposing patterns of expression change that defy the norm of function between the two partners, indicating a possible functional alteration in one or both partner proteins.
Interpreted against the framework of field cancerization, the findings carry implications beyond the tumor itself. KAISO’s reported role in determining the field in oral cancer patients, combined with this study’s sampling of the periphery and opposing mucosa, provides a starting point for asking whether the field can be read through this protein pair. Aberrant p53 accumulation is already used in research settings as an indicator of malignant and premalignant change, and a companion marker that moves in the opposite direction could sharpen assessments of surgical margins and apparently normal mucosa. The authors also frame the work around clinicopathological characteristics, connecting the geography of expression to the clinical anatomy of the disease. The study’s design does impose natural limits: immunohistochemistry measures protein abundance and position rather than TP53 mutation status, optical density remains a semi-quantitative surrogate, and a cohort of fifty patients is modest — all reasons the central claim is presented as a possibility rather than a proven mechanism.
The study, published open access in BMC Cancer as a peer-reviewed, citable accepted manuscript carrying a permanent DOI ahead of its final version of record, was a self-funded investigation, with laboratory support provided by the Dow Research Institute of Biotechnology and Bio-Sciences. Received in June 2024 and accepted in August 2026, the paper arrives at a moment when cancer biologists are actively re-examining how p53’s vast regulatory network is hijacked during tumor development. The immediate next questions are molecular and mechanical: whether KAISO’s downward slide reflects failed transcriptional activation by p53, protein instability, or redistribution within the cell, and whether the subcellular shifts hold up in larger cohorts and at the level of direct protein interaction. Whatever those answers turn out to be, the Karachi team’s message already travels far beyond the oral surgery clinic: in cancer, even the most trusted partnerships in the cell’s defense system can be rewritten, and the evidence may be visible in a single stained slide.
Subject of Research: Expressional patterns and subcellular distribution of p53 (TP53) and KAISO (ZBTB33) in oral squamous cell carcinoma and their association with field cancerization
Subject of Research: Cancer
Article Title: Expressional patterns of p53: an association with KAISO, clinicopathological characteristics, and field cancerization of OSCC
Article References: Ahmed, S., Khan, S., Qureshi, M. A., Jamil, S., Anis, M., & ahmed, W. (2026). Expressional patterns of p53: an association with KAISO, clinicopathological characteristics, and field cancerization of OSCC. BMC Cancer. https://doi.org/10.1186/s12885-026-16724-6
Image Credits: AI Generated
DOI: 10.1186/s12885-026-16724-6
Keywords: TP53, p53, KAISO, ZBTB33, oral squamous cell carcinoma, oral cancer, field cancerization, immunohistochemistry, tumor suppressor, buccal mucosa, nuclear-cytoplasmic localization, surgical margins
Cite Scienmag News
APA MLA Chicago
Rowan B. (August 29, 2026). p53 expression patterns link KAISO and field cancerization in oral cancer. Scienmag. https://scienmag.com/p53-expression-patterns-link-kaiso-and-field-cancerization-in-oral-cancer/
Rowan B. “p53 expression patterns link KAISO and field cancerization in oral cancer.” Scienmag, 29 August 2026, https://scienmag.com/p53-expression-patterns-link-kaiso-and-field-cancerization-in-oral-cancer/. Accessed 29 August 2026.
Rowan B. “p53 expression patterns link KAISO and field cancerization in oral cancer.” Scienmag. August 29, 2026. https://scienmag.com/p53-expression-patterns-link-kaiso-and-field-cancerization-in-oral-cancer/
Copy citation Download RIS
Tags: biomarkers for early detection of oral malignanciescancer biomarker analysis in oral tissuesDNA damage response in oral cancerfield cancerization in oral tumorsimpact of TP53 mutations on oral cancer developmentKAISO protein function in cancer progressionKAISO transcription factor in cancermolecular alterations in field cancerizationmolecular alterations in oral carcinogenesismolecular mechanisms of field cancerization in oral tumorsmolecular mechanisms of oral squamous cell carcinomap53 and KAISO expression patternsp53 and KAISO expression patterns in squamous cell carcinomap53 tumor suppressor in oral cancerp53 tumor suppressor role in oral cancerprotein interactions in tumor progressionprotein partner disruption in head and neck cancersrelationship between DNA damage response and protein partnersrole of p53 in field cancerizationsubcellular localization changes of p53 and KAISO in oral cancersubcellular localization of p53 and KAISOtumor suppressor gene mutations in oral cancer
